Howard A. Fine, MD, Joins NYU Langone Medical Center

New Neuro-oncologist to Advance Research and Education at NYU Cancer Institute

August 23, 2012 - 3:42pm

NYU Langone Medical Center announced today that Howard A. Fine, MD, has been appointed the Anne Murnick Cogan and David H. Cogan Professor of Oncology, chief of the Division of Hematology and Medical Oncology, director of the Brain Tumor Center, and deputy director of the NYU Cancer Institute. His appointment is effective September 5, 2012.

A recognized leader in neuro-oncology and medical research, Dr. Fine joins NYU Langone from the National Cancer Institute (NCI) for Cancer Research in Bethesda, MD where he is the chief of the Neuro-Oncology Branch (NOB) and holds a joint appointment with the National Institute of Neurological Disorders and Stroke (NINDS), as an adjunct investigator. In his new role, he will have a wide range of responsibilities including directing clinical programs in solid tumor oncology, developmental therapeutics, malignant hematology and experimental hematology.

“We are delighted to welcome Dr. Fine to the NYU Langone faculty. As one of today’s leading neuro-oncologists and a visionary leader, he brings a wealth of expertise and experience in research to treat brain tumors of adults and children,” said William L. Carroll, MD, the Julie and Edward J. Minskoff Professor of Pediatrics, Department of Pediatrics, professor, Department of Pathology and director, NYU Cancer Institute at NYU Langone. “He will continue to build on the world-class care our patients have already come to expect us to deliver.”

Dr. Fine completed both his internship and his residency in Internal Medicine at the Hospital of The University of Pennsylvania. He later completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA, a teaching affiliate of Harvard Medical School. Before joining the NIH in 2000, Dr. Fine was both director of the Neuro-Oncology Disease Center at Dana-Farber Cancer Institute and of the Neuro-Oncology Program at the Dana-Farber/Harvard Cancer Center. While at NCI, he developed one of the preeminent brain tumors programs in the world.


Media Inquiries:

Christopher Rucas